Last reviewed · How we verify

Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab

ARCAGY/ GINECO GROUP · Phase 2 active Small molecule

Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab is a Small molecule drug developed by ARCAGY/ GINECO GROUP. It is currently in Phase 2 development.

At a glance

Generic namePembrolizumab Injectable Product - Chemotherapy - Bevacizumab
SponsorARCAGY/ GINECO GROUP
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab

What is Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab?

Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab is a Small molecule drug developed by ARCAGY/ GINECO GROUP.

Who makes Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab?

Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab is developed by ARCAGY/ GINECO GROUP (see full ARCAGY/ GINECO GROUP pipeline at /company/arcagy-gineco-group).

What development phase is Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab in?

Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab is in Phase 2.

Related